Teacher Retirement System of Texas Has $212,000 Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Teacher Retirement System of Texas reduced its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMRFree Report) by 18.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,316 shares of the company’s stock after selling 1,885 shares during the quarter. Teacher Retirement System of Texas’ holdings in Kymera Therapeutics were worth $212,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of KYMR. Vanguard Group Inc. boosted its holdings in shares of Kymera Therapeutics by 4.9% in the third quarter. Vanguard Group Inc. now owns 3,925,213 shares of the company’s stock valued at $54,560,000 after buying an additional 182,125 shares during the period. Rock Springs Capital Management LP raised its stake in shares of Kymera Therapeutics by 1.1% in the 3rd quarter. Rock Springs Capital Management LP now owns 1,504,351 shares of the company’s stock valued at $20,910,000 after purchasing an additional 16,800 shares during the period. FMR LLC lifted its holdings in shares of Kymera Therapeutics by 3.9% in the third quarter. FMR LLC now owns 870,547 shares of the company’s stock valued at $12,101,000 after purchasing an additional 32,335 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Kymera Therapeutics by 23.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 463,533 shares of the company’s stock worth $6,443,000 after buying an additional 86,585 shares during the period. Finally, Barclays PLC boosted its position in shares of Kymera Therapeutics by 1.2% during the third quarter. Barclays PLC now owns 389,476 shares of the company’s stock worth $5,414,000 after buying an additional 4,493 shares during the period.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock opened at $32.16 on Friday. The business has a fifty day simple moving average of $36.20 and a two-hundred day simple moving average of $32.36. Kymera Therapeutics, Inc. has a 1 year low of $9.60 and a 1 year high of $45.31. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of -12.81 and a beta of 2.31.

Kymera Therapeutics (NASDAQ:KYMRGet Free Report) last announced its earnings results on Thursday, May 2nd. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.04. The business had revenue of $10.30 million during the quarter, compared to the consensus estimate of $14.24 million. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 31.92%. Kymera Therapeutics’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.70) EPS. As a group, equities analysts anticipate that Kymera Therapeutics, Inc. will post -2.86 earnings per share for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 71,764 shares of the company’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $40.46, for a total value of $2,903,571.44. Following the transaction, the director now directly owns 806,697 shares of the company’s stock, valued at approximately $32,638,960.62. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Kymera Therapeutics news, major shareholder Venture Fund X. L.P. Atlas sold 115,090 shares of the firm’s stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $42.23, for a total transaction of $4,860,250.70. Following the transaction, the insider now owns 4,676,075 shares in the company, valued at approximately $197,470,647.25. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Bruce Booth sold 71,764 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $40.46, for a total value of $2,903,571.44. Following the completion of the transaction, the director now owns 806,697 shares in the company, valued at approximately $32,638,960.62. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 423,529 shares of company stock worth $17,815,113. Company insiders own 15.82% of the company’s stock.

Analysts Set New Price Targets

KYMR has been the subject of a number of recent research reports. Wolfe Research initiated coverage on Kymera Therapeutics in a research report on Thursday, February 15th. They set a “peer perform” rating for the company. HC Wainwright reissued a “buy” rating and set a $46.00 price target on shares of Kymera Therapeutics in a research report on Friday, May 24th. Truist Financial increased their price objective on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Piper Sandler lifted their target price on Kymera Therapeutics from $39.00 to $56.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Finally, Oppenheimer reduced their price target on Kymera Therapeutics from $53.00 to $52.00 and set an “outperform” rating for the company in a research report on Friday, May 3rd. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $42.70.

View Our Latest Stock Analysis on Kymera Therapeutics

Kymera Therapeutics Profile

(Free Report)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

See Also

Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. (NASDAQ:KYMRFree Report).

Institutional Ownership by Quarter for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.